Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
Beijing Pilots The DRG External Payment Mode
DRG refers to the diagnosis-related group used to classify the patient and set up a system to ensure the care provided is necessary. The National Healthcare Security Administration will pay the hospital a predetermined amount according to a patient’s DRG.
Jul 16, 2022 12:12 AM
China Mobile Returns to A-share Market Planning to Issue 965 Mn Shares
The announcement shows that the funds raised by the telecommunication company will be used for projects such as 5G boutique network construction, new Cloud infrastructure construction, gigabit smart home construction, new-generation information technology research and development, digital intelligence ecology construction, and so on.
May 18, 2021 11:28 AM
Temu Unleashed: A Journey of Skepticism, Revelation, and the Quest to Redefine E-commerce
Jan 06, 2024 12:16 PM